Best AI Index Fund to Buy
Over the last two years, companies with a focus on…
Buy
58
XPOF Quote, Financials, Valuation and Earnings
Last price:
$9.01
Seasonality move
:
11.09%
Day range:
$9.00 - $9.38
52-week range:
$6.64 - $18.95
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.93x
P/B ratio:
--
Volume:
558K
Avg. volume:
725.5K
1-year change:
-3.64%
Market cap:
$314.7M
Revenue:
$320.3M
EPS (TTM):
-$2.04
Analysts' Opinion
-
Consensus RatingXponential Fitness has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.30, Xponential Fitness has an estimated upside of 47.61% from its current price of $9.01.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $9.00 representing 0.11% downside risk from its current price of $9.01.
Fair Value
-
According to the consensus of 8 analysts, Xponential Fitness has 47.61% upside to fair value with a price target of $13.30 per share.
XPOF vs. S&P 500
-
Over the past 5 trading days, Xponential Fitness has overperformed the S&P 500 by 5.29% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Xponential Fitness does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Xponential Fitness revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Xponential Fitness reported revenues of $76.9M.
Earnings Growth
-
Xponential Fitness has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Xponential Fitness reported earnings per share of -$0.10.
Enterprise value:
560.1M
EV / Invested capital:
--
Price / LTM sales:
0.93x
EV / EBIT:
294.90x
EV / Revenue:
1.76x
PEG ratio (5yr expected):
-0.05x
EV / Free cash flow:
63.74x
Price / Operating cash flow:
33.53x
Enterprise value / EBITDA:
19.47x
Gross Profit (TTM):
$210.4M
Return On Assets:
-14.72%
Net Income Margin (TTM):
-21.05%
Return On Equity:
--
Return On Invested Capital:
-80.87%
Operating Margin:
3.85%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $263.5M | $326.9M | $317.7M | $79.7M | $76.9M | |
| Gross Profit | $176.4M | $224.9M | $210.4M | $53.6M | $51.5M | |
| Operating Income | $33.2M | $37.2M | $8.9M | $12.5M | $3M | |
| EBITDA | $38.9M | $65.3M | -$34.5M | $12.2M | $12.2M | |
| Diluted EPS | -$3.54 | -$1.05 | -$2.04 | -$0.29 | -$0.10 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $30.7M | $54.8M | $79M | $87.8M | $100.1M | |
| Total Assets | $340.6M | $434.6M | $484.3M | $508.4M | $412.4M | |
| Current Liabilities | $55.6M | $62M | $77.2M | $92.4M | $122.9M | |
| Total Liabilities | $330.5M | $699.8M | $763M | $722.7M | $726.2M | |
| Total Equity | $10.1M | -$265.2M | -$278.8M | -$214.3M | -$313.7M | |
| Total Debt | $192.6M | $130.3M | $261.9M | $327.4M | $360.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $60.5M | $24M | $14.8M | $2.7M | $5.8M | |
| Cash From Investing | -$14.8M | -$18.5M | -$5.9M | -$9.2M | -$997K | |
| Cash From Financing | -$33.4M | -$6.5M | $6.5M | -$3.4M | $5M | |
| Free Cash Flow | $43.9M | $16.1M | $8.8M | $1.3M | $5M | |
XPOF
Sector
Market Cap
$314.7M
$410.3M
Price % of 52-Week High
47.55%
71.02%
Dividend Yield
0%
0%
Shareholder Yield
--
3.91%
1-Year Price Total Return
-3.64%
-13.51%
Beta (5-Year)
--
0.782
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
-8.51%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.73
200-day SMA
Sell
Level
$12.56
Bollinger Bands (100)
Sell
Level
7.71 - 15.33
Chaikin Money Flow
Sell
Level
-7M
20-day SMA
Buy
Level
$8.78
Relative Strength Index (RSI14)
Buy
Level
53.15
ADX Line
Buy
Level
12.99
Williams %R
Neutral
Level
-39.1304
50-day SMA
Buy
Level
$8.21
MACD (12, 26)
Buy
Level
0.12
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Sell
Level
-9.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.7637)
Sell
CA Score
(Annual)
Level (-4.7071)
Buy
Beneish M-Score
(Annual)
Level (-3.8998)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (9.0575)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Xponential Fitness Inc is a curator of boutique fitness brands. Its diversified portfolio of brands includes Club Pilates, a Pilates brand in the United States; CycleBar, an indoor cycling brand in the United States; StretchLab, a concept offering one-on-one and group stretching services; Row House, a high-energy, low-impact indoor rowing workout; AKT, a dance-based cardio workout combining toning, interval and circuit training; YogaSix a franchised yoga brand; Pure Barre, a total body workout that uses the ballet barre to perform small isometric movements; Stride, a treadmill-based cardio and strength training concept; Rumble, a boxing-inspired full-body workout; and BFT, a functional training and strength-based program. Its key revenue source is franchise income.
Stock Forecast FAQ
In the current month, XPOF has received 3 Buy ratings 5 Hold ratings, and 0 Sell ratings. The XPOF average analyst price target in the past 3 months is $13.30.
-
Where Will Xponential Fitness Stock Be In 1 Year?
According to analysts, the consensus estimate is that Xponential Fitness share price will rise to $13.30 per share over the next 12 months.
-
What Do Analysts Say About Xponential Fitness?
Analysts are divided on their view about Xponential Fitness share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Xponential Fitness is a Sell and believe this share price will drop from its current level to $9.00.
-
What Is Xponential Fitness's Price Target?
The price target for Xponential Fitness over the next 1-year time period is forecast to be $13.30 according to 8 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is XPOF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Xponential Fitness is a Hold. 5 of 8 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of XPOF?
You can purchase shares of Xponential Fitness via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Xponential Fitness shares.
-
What Is The Xponential Fitness Share Price Today?
Xponential Fitness was last trading at $9.01 per share. This represents the most recent stock quote for Xponential Fitness. Yesterday, Xponential Fitness closed at $9.01 per share.
-
How To Buy Xponential Fitness Stock Online?
In order to purchase Xponential Fitness stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
